Capital Research Global Investors Biomarin Pharmaceutical Inc Transaction History

Capital Research Global Investors

$443 Billion
Q2 2024

A detailed history of Capital Research Global Investors transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Capital Research Global Investors holds 9,692,566 shares of BMRN stock, worth $684 Million. This represents 0.18% of its overall portfolio holdings.

Number of Shares

9,692,566

Previous 6,520,661 48.64%

Holding current value

$684 Million

Previous $570 Million 40.12%

% of portfolio

0.18%

Previous 0.13%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$74.43 - $92.22 $236 Million - $293 Million	3,171,905 Added 48.64%	9,692,566 $798 Million
Q1 2024 May 14, 2024	SELL	$83.81 - $99.0 $357 Million - $421 Million	-4,253,980 Reduced 39.48%	6,520,661 $570 Million
Q4 2023 Feb 13, 2024	BUY	$76.22 - $98.51 $363 Million - $469 Million	4,756,671 Added 79.04%	10,774,641 $1.04 Billion
Q3 2023 Nov 13, 2023	SELL	$85.07 - $94.48 $62.8 Million - $69.7 Million	-738,062 Reduced 10.92%	6,017,970 $532 Million
Q2 2023 Aug 11, 2023	SELL	$86.68 - $100.3 $39.3 Million - $45.4 Million	-452,927 Reduced 6.28%	6,756,032 $586 Million
Q1 2023 May 15, 2023	BUY	$87.74 - $117.27 $137 Million - $183 Million	1,557,958 Added 27.57%	7,208,959 $701 Million
Q4 2022 Feb 14, 2023	BUY	$80.93 - $108.63 $57.8 Million - $77.6 Million	714,261 Added 14.47%	5,651,001 $585 Million
Q3 2022 Nov 14, 2022	BUY	$82.16 - $96.94 $114,531 - $135,134	1,394 Added 0.03%	4,936,740 $418 Million
Q2 2022 Aug 15, 2022	SELL	$71.48 - $86.85 $318 Million - $387 Million	-4,452,610 Reduced 47.43%	4,935,346 $409 Million
Q1 2022 May 16, 2022	SELL	$74.28 - $92.69 $244 Million - $304 Million	-3,284,052 Reduced 25.92%	9,387,956 $724 Million
Q4 2021 Feb 14, 2022	SELL	$71.72 - $91.47 $357 Million - $455 Million	-4,973,431 Reduced 28.19%	12,672,008 $1.12 Billion
Q3 2021 Nov 15, 2021	SELL	$74.77 - $85.47 $332 Million - $380 Million	-4,440,950 Reduced 20.11%	17,645,439 $1.36 Billion
Q2 2021 Aug 16, 2021	BUY	$75.51 - $84.79 $756,912 - $849,934	10,024 Added 0.05%	22,086,389 $1.84 Billion
Q1 2021 May 14, 2021	SELL	$74.73 - $90.69 $193,700 - $235,068	-2,592 Reduced 0.01%	22,076,365 $1.67 Billion
Q4 2020 Feb 12, 2021	BUY	$72.61 - $90.2 $1.14 Million - $1.42 Million	15,695 Added 0.07%	22,078,957 $1.94 Billion
Q3 2020 Nov 13, 2020	SELL	$71.87 - $131.03 $180,681 - $329,409	-2,514 Reduced 0.01%	22,063,262 $1.68 Billion
Q2 2020 Aug 14, 2020	BUY	$79.55 - $124.22 $2 Million - $3.13 Million	25,158 Added 0.11%	22,065,776 $2.72 Billion
Q1 2020 May 15, 2020	BUY	$71.37 - $96.85 $2.61 Million - $3.54 Million	36,553 Added 0.17%	22,040,618 $1.86 Billion
Q4 2019 Feb 18, 2020	BUY	$64.27 - $86.37 $19 Million - $25.6 Million	296,401 Added 1.37%	22,004,065 $1.86 Billion
Q3 2019 Nov 14, 2019	BUY	$67.4 - $85.11 $136 Million - $171 Million	2,011,459 Added 10.21%	21,707,664 $1.46 Billion
Q2 2019 Aug 14, 2019	BUY	$80.35 - $93.9 $156 Million - $183 Million	1,947,144 Added 10.97%	19,696,205 $1.69 Billion
Q1 2019 May 15, 2019	SELL	$84.2 - $98.62 $46.7 Million - $54.7 Million	-555,102 Reduced 3.03%	17,749,061 $1.58 Billion
Q4 2018 Feb 14, 2019	SELL	$80.14 - $106.07 $99.8 Million - $132 Million	-1,244,970 Reduced 6.37%	18,304,163 $1.56 Billion
Q3 2018 Nov 14, 2018	SELL	$93.92 - $105.72 $192 Million - $216 Million	-2,043,999 Reduced 9.47%	19,549,133 $1.9 Billion
Q2 2018 Aug 14, 2018	BUY	$76.01 - $99.03 $7.01 Million - $9.14 Million	92,281 Added 0.43%	21,593,132 $2.03 Billion
Q1 2018 May 15, 2018	SELL	$77.67 - $92.63 $621 - $741	-8 Reduced -0.0%	21,500,851 $1.74 Billion
Q4 2017 Feb 14, 2018	BUY	$80.76 - $95.13 $52.5 Million - $61.9 Million	650,258 Added 3.12%	21,500,859 $1.92 Billion
Q3 2017 Nov 14, 2017	BUY	$80.6 - $94.95 $1.68 Billion - $1.98 Billion	20,850,601	20,850,601 $1.94 Billion

Others Institutions Holding BMRN

# of Institutions

632

Shares Held

185M

Call Options Held

1.63M

Put Options Held

1.2M

View Full List

About BIOMARIN PHARMACEUTICAL INC

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $13.1B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

More about BMRN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Capital Research Global Investors, based on Form 13F filings with the SEC.

News

Stay updated on Capital Research Global Investors with notifications on news.

Account

Capital Research Global Investors Biomarin Pharmaceutical Inc Transaction History